Compare FedEx Corporation (FDX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Illumina, Inc. — how do they compare? FedEx Corporation trades at $291.66 (market cap $69.04B), while Illumina, Inc. trades at $278 (market cap $39.95B). The key difference: FedEx Corporation is the larger of the two by market cap, and FedEx Corporation pays a 1.67% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Illumina, Inc. for 83 Days on average.
| FDX | ILMN | |
|---|---|---|
Market Cap | $69.04B | $39.95B |
Volume | 1,287,367 | 3,169,503 |
Sector | Industrials | Health |
52-Week High | $339.35 | $293.69 |
52-Week Low | $180.87 | $91.00 |
Typical Hold Time | 87 Days | 83 Days |
Enterprise Value | $98.68B | $41.31B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.71, up 0.92% today, with a bearish technical signal but strong fundamentals including a P/E of 15.73 and net income margin of 4.68%. Recent Q1 2026 earnings beat expectations at $6.31 EPS. The company announced a $300 million electric truck order from Harbinger (TechCrunch, 2026-09-30) and a $1.22 dividend payable October 1, 2026. Cash flow from operations was $7.04B in 2025, with a projected rebound to $8.9B in 2026.
The outlook is mixed: analyst consensus is a Buy with a $307.55 price target, but rising fuel costs and geopolitical tensions pose margin risks. Earnings growth and cost-cutting initiatives support upside, while technical resistance near $294 may limit near-term gains. Debt-to-asset ratio is expected to rise to 25.99% in 2026, adding financial leverage concerns.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
